SCFAs treatment may also constitute substrates for gut mucosa and ameliorate intestinal damage, by restoration of glutathione levels and reduction in proinflammatory mediators, including nitric oxide (NO) and tumor necrosis factor-α (TNF-α) in rat models of colitis (71). This evidence concerns the gene TNF and colitis.